Medical devices covers diagnostic, therapeutic, surgical, monitoring and assistive equipment and the consumables and software around them - from imaging systems and in-vitro diagnostics to implants, surgical instruments and wearables. Markets are driven by aging populations, chronic-disease prevalence, reimbursement and a shift toward minimally invasive and connected care.
How Credence Research isolates regulatory pathway timing, reimbursement risk, and component sourcing exposure across medical devices.
| Coverage Universe | Regulatory pipeline, reimbursement, and manufacturing tracking across: Diagnostic Imaging Systems, In-Vitro Diagnostics, Surgical Instruments and Robotics, Implantable Devices, Patient Monitoring Systems, and Wearable and Connected Health Devices. |
| Target Decision-Makers | Chief Regulatory and Quality Officers, Heads of Reimbursement Strategy, Medical Device Corporate Development Directors, Healthcare Private Equity investment leads, and investment committees requiring independent asset due diligence. |
| Primary Value Proposition | Aggregated device market totals mask real regulatory and reimbursement timing risk. We measure the financial impact of FDA clearance pathway delays, hospital procurement cycle length, and component sourcing risk on realistic device commercialization timelines. |
| Geographic Corridors | United States FDA 510(k) and premarket approval pathways, European Union Medical Device Regulation compliance transition, Chinese and Indian domestic device manufacturing localization mandates, and Japanese and South Korean device reimbursement frameworks. |
| Forecast Horizon | Granular 5- to 8-year rolling forecast models (2026 to 2034) updated via primary regulatory clearance tracking and hospital purchasing group procurement cycles. |
| Research Methodology | Primary interviews across regulatory affairs directors, hospital procurement managers, and device component suppliers, combined with bottom-up bill-of-materials cost modeling rather than secondary press aggregation. |
Systematic tracking of regulatory timelines, reimbursement risk, and component sourcing across medical device categories.
| Vertical Sector | Primary Metric Tracked | Executive Buyer Strategic Focus | Credence Intelligence Deliverable |
|---|---|---|---|
| Diagnostic Imaging Systems | Installed base replacement cycle, AI-assisted diagnostic adoption | Point-of-care imaging miniaturization, AI diagnostic software integration | Replacement cycle models, AI adoption tracking |
| In-Vitro Diagnostics | Assay throughput costs, molecular diagnostic adoption rates | Point-of-care testing expansion, companion diagnostic development | Throughput cost models, adoption rate benchmarks |
| Surgical Instruments & Robotics | Robotic system placement rates, procedure volume per system | Minimally invasive procedure expansion, surgical robotics platform competition | Placement rate tracking, procedure volume models |
| Implantable Devices | Regulatory approval timeline, component material sourcing risk | Biocompatible material innovation, remote monitoring-enabled implants | Approval timeline tracking, sourcing risk scores |
| Patient Monitoring Systems | Hospital procurement cycle length, interoperability standard compliance | Remote patient monitoring expansion, predictive deterioration alerting | Procurement cycle models, compliance cost tracking |
| Wearable & Connected Health Devices | Consumer versus clinical-grade device cost differential, data platform integration cost | Clinical-grade wearable reimbursement pathways, chronic disease remote management | Cost differential models, integration cost benchmarks |
In-depth research modules and customized commercial advisory for medical device executives.
| Market | Base Size | Forecast | CAGR | Report |
|---|---|---|---|---|
| NPHP5 Retinal Degeneration Treatment Market Size and Forecast 2032 | USD 25.7 million | USD 285.22 million | 35.10% | View → |
| Organ-on-Chip Market Size, Share and Growth Report 2032 | USD 154.8 Million | USD 1698.73 Million | 34.91% | View → |
| Neuromorphic Computing ASIC Market Size, Growth and Forecast 2032 | USD 246.04 million | USD 2,186.57 million | 31.40% | View → |
| AI in Operating Room Market Size, Growth and Forecast 2032 | USD 528.18 million | USD 4,359.16 million | 30.19% | View → |
| Vein Illuminator Market Size, Growth, Share and Forecast 2032 | USD 81.13 million | USD 643.29 million | 29.54% | View → |
| Generative AI in SaMD Market Size to Reach USD 14.2 Billion by 2034 | USD 1.4 billion | USD 14.2 billion | 29.4% | View → |
| Invisible Orthodontics Market Size, Share and Forecast 2032 | USD 6,554.51 million | USD 45,480.41 million | 27.46% | View → |
| Vein Illumination Devices Market Size, Growth and Forecast 2032 | USD 152 million | USD 984.2 million | 26.3% | View → |
APAC sleep apnea devices market grows from USD 2.40 billion in 2025 to USD 5.34 billion by 2035, at an 8.28% CAGR, as diagnosis and home PAP therapy expand.
Asia Pacific surgical drills market grows from USD 381.5 million in 2025 to USD 744.7 million by 2035, at a 6.91% CAGR, led by China and dental demand.
Australia Group 2 powered mobility devices market rises from USD 35.8 million in 2025 to USD 84.1 million by 2035, led by NDIS demand and new aged-care funding.
Australia blood group typing market worth USD 55.3 million in 2025 will reach USD 88.5 million by 2035 at a 4.81% CAGR on transfusion and antenatal testing.
Australia extracorporeal shock wave lithotripsy market worth USD 11.5 million in 2025 is set to reach USD 12.3 million by 2035 at a 0.63% CAGR.
Australia dual-energy X-ray absorptiometry market worth USD 12.2 million in 2025 will reach USD 22.5 million by 2035 at a 6.28% CAGR as bone testing grows.
Australia dental imaging market worth USD 69.0 million in 2025 will reach USD 160.0 million by 2035 at an 8.78% CAGR as clinics adopt 3D scans and software.
Australia needle-free injectors market worth USD 60.5 million in 2025 will reach USD 144.8 million by 2035 at a 9.13% CAGR on diabetes and home care demand.
Australia hypodermic syringes and needles market worth USD 130.3 million in 2025 will reach USD 215.6 million by 2035 at a 5.17% CAGR on chronic care demand.
Australia medical X-ray generator market worth USD 35.5 million in 2025 will reach USD 53.5 million by 2035 at a 4.18% CAGR as hospitals renew imaging fleets.
Australia hemostatic instruments market worth USD 66.5 million in 2025 will reach USD 128.6 million by 2035 at a 6.82% CAGR as surgery volumes rise.
APAC peripheral artery disease market rises from USD 1.91 billion in 2025 to USD 4.25 billion by 2035, at an 8.25% CAGR, as diabetes and limb ischemia grow.
Asia-Pacific left atrial appendage closure devices market rises from USD 419.5 million in 2025 to USD 1.78 billion by 2035, at a 15.42% CAGR, on trial data.
Asia-Pacific suction catheters market grows from USD 133.5 million in 2025 to USD 320.4 million by 2035, at a 9.17% CAGR, as ICU beds and closed systems expand.
Asia Pacific spine biologics market grows from USD 439.5 million in 2025 to USD 834.0 million by 2035, at a 6.60% CAGR, as aging lifts fusion surgery demand.
Australia dental bonding agents market worth USD 18.2 million in 2025 will reach USD 33.2 million by 2035 at a 6.20% CAGR as bonded resin replaces amalgam.
Wearable medical devices market worth USD 41.77 billion in 2025 is set to reach USD 113.37 billion by 2035 at a 10.50% CAGR as glucose and heart monitors grow.
Ophthalmic devices market worth USD 4.19 billion in 2025 is set to reach USD 6.98 billion by 2035 at a 5.24% CAGR as eye imaging and AI screening spread.
Asia Pacific veterinary surgical instruments sales grow from USD 351.5 million in 2025 to USD 866.9 million by 2035, led by China and specialist surgery.
Australia contact lenses market at USD 252.5 million in 2025 will reach USD 432.7 million by 2035 at a 5.29% CAGR as daily and myopia lenses gain ground.
Surgical equipment market worth USD 18.57 billion in 2025 is forecast to reach USD 34.56 billion by 2035 at a 6.41% CAGR, led by sutures and staplers.
Wound care products market worth USD 27.57 billion in 2025 is set to reach USD 44.25 billion by 2035 at a 4.84% CAGR as chronic wounds and home therapy rise.
Aging, domestic Chinese implants and adaptive therapy lift Asia Pacific neuromodulation device sales from USD 1.29 billion in 2025 to USD 4.22 billion by 2035.
Australia clear aligners market worth USD 134.5 million in 2025 will reach USD 427.2 million by 2035 at a 12.28% CAGR as general dentists adopt aligners.
B2B clients served worldwide
Market research reports published
Of Fortune 1,000 companies as clients
Forecast horizon in every report
Get a free sample report or speak with a research analyst about your specific segment or region.